Sarepta Therapeutics | SRPT - Operating Profit


Sarepta Therapeutics reported $358.43M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amgen USD 3.83B 130M Mar/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Biogen USD 514.3M 128.8M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Gilead Sciences USD 2.68B 284M Mar/2026
Incyte USD 324.17M 59.7M Mar/2026
Insmed USD -200.28M 49.43M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Moderna USD -1.39B 531M Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 4.99B 340M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 1.94B 239M Mar/2026
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Tectonic Therapeutic USD -27.3M 5.78M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026